NCT03409432View on ClinicalTrials.gov

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 16, 2018

Primary Completion Date

July 16, 2025

Study Completion Date

July 16, 2025

Conditions

Lymphomatoid PapulosisPrimary Cutaneous Anaplastic Large Cell LymphomaRecurrent Primary Cutaneous T-Cell Non-Hodgkin LymphomaRecurrent T-Cell Non-Hodgkin LymphomaRefractory Primary Cutaneous T-Cell Non-Hodgkin LymphomaStage I Cutaneous T-Cell Non-Hodgkin LymphomaStage II Cutaneous T-Cell Non-Hodgkin LymphomaStage III Cutaneous T-Cell Non-Hodgkin LymphomaStage IV Cutaneous T-Cell Non-Hodgkin Lymphoma

Interventions

DRUG

Brentuximab Vedotin

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Lenalidomide

Given PO

Trial Locations (1)

43210

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors

lead

John Reneau

OTHER

NCT03409432 - Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma | Biotech Hunter | Biotech Hunter